These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22681706)

  • 1. BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China.
    Zheng X; Xia T; Lin L; Gao S; Lee Y; Yu Y; Wei S; Gao M
    World J Surg Oncol; 2012 Jun; 10():104. PubMed ID: 22681706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of solitary and multifocal papillary thyroid carcinoma - a retrospective study of 368 patients.
    Zheng XQ; Wang C; Xu M; Yu Y; Yun XW; Jia YS; Wei SF; Ren XB; Gao M
    Chin Med J (Engl); 2012 Dec; 125(24):4434-9. PubMed ID: 23253715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer.
    Campennì A; Ruggeri RM; Giuffrè G; Siracusa M; Alibrandi A; Cardile D; La Torre F; Lanzafame H; Giacoppo G; Ieni A; Trimarchi F; Tuccari G; Baldari S
    Nucl Med Commun; 2021 Jun; 42(6):611-618. PubMed ID: 33625185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients.
    Wang W; Su X; He K; Wang Y; Wang H; Wang H; Zhao Y; Zhao W; Zarnegar R; Fahey TJ; Teng X; Teng L
    Cancer; 2016 Jan; 122(2):198-206. PubMed ID: 26506214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
    PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
    Kim YS; Kim JS; Bae JS; Park WC
    World J Surg Oncol; 2013 May; 11():99. PubMed ID: 23687957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
    Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
    Sancisi V; Nicoli D; Ragazzi M; Piana S; Ciarrocchi A
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1745-9. PubMed ID: 22740704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma.
    Sezer A; Celik M; Yilmaz Bulbul B; Can N; Tastekin E; Ayturk S; Ustun F; Guldiken S; Sut N
    Bosn J Basic Med Sci; 2017 May; 17(2):144-151. PubMed ID: 28284178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology.
    Moon HJ; Kwak JY; Kim EK; Choi JR; Hong SW; Kim MJ; Son EJ
    Ann Surg Oncol; 2009 Nov; 16(11):3125-31. PubMed ID: 19644722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
    Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.
    Park VY; Kim EK; Moon HJ; Yoon JH; Kwak JY
    Medicine (Baltimore); 2016 Jul; 95(29):e4292. PubMed ID: 27442672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience.
    Pelizzo MR; Boschin IM; Barollo S; Pennelli G; Toniato A; Zambonin L; Vianello F; Piotto A; Ide EC; Pagetta C; Sorgato N; Torresan F; Girelli ME; Nacamulli D; Mantero F; Mian C
    Clin Chem Lab Med; 2011 Feb; 49(2):325-9. PubMed ID: 21175381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
    Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
    Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.
    Alzahrani AS; Xing M
    Endocr Relat Cancer; 2013 Feb; 20(1):13-22. PubMed ID: 23132792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synergic effect of BRAF
    Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
    Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
    Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
    Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.